| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EMBRYONIC STEM CELLS |
1 Department of Medicine and Physiology, Cardiovascular Research Laboratory, University of California Los Angeles, Los Angeles, California, USA
2 Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, California, USA
3 Department of Surgery, Regenerative Bioengineering and Repair Laboratory, University of California Los Angeles, Los Angeles, California, USA
4 Department of Biological Chemistry, and Molecular Biology Institute, Johnson Comprehensive Cancer Center and Institute for Stem Cell Biology and Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
* To whom correspondence should be addressed. E-mail: rmaclellan{at}mednet.ucla.edu.
 |
Abstract |
|---|
Forced expression of the four transcription factors Oct4, Sox2, c-Myc, and Klf4 is sufficient to confer a pluripotent state upon the murine fibroblast genome, generating induced pluripotent stem (iPS) cells. Although the differentiation potential of these cells is thought to be equivalent to that of embryonic stem (ES) cells, it has not been rigorously determined. In this study, we sought to identify the capacity of iPS cells to differentiate into Flk1-positive progenitors and their mesodermal progeny, including cells of the cardiovascular and hematopoietic lineages. Immunostaining of tissues from iPS cell-derived chimeric mice demonstrated that iPS cells could contribute in vivo to cardiomyocytes, smooth muscle cells, endothelial cells, and hematopoietic cells. To compare the in vitro differentiation potential of murine ES and iPS cells, we either induced embryoid body (EB) formation of each cell type or cultured the cells on collagen type IV (ColIV), an extracellular matrix protein that had been reported to direct murine ES cell differentiation to mesodermal lineages. EB formation and exposure to ColIV both induced iPS cell differentiation into cells that expressed cardiovascular and hematopoietic markers. To determine whether ColIV-differentiated iPS cells contained a progenitor cell with cardiovascular and hematopoietic differentiation potential, Flk1-positive cells were isolated by magnetic cell sorting and exposed to specific differentiation conditions, which induced differentiation into functional cardiomyocytes, smooth muscle cells, endothelial cells, and hematopoietic cells. Our data demonstrate that murine iPS cells, like ES cells, can differentiate into cells of the cardiovascular and hematopoietic lineages and therefore may represent a valuable cell source for applications in regenerative medicine.
______________________________________________________________________________
Author contributions: K.S.-L. and K.E.R.: collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; E.A.: data analysis and interpretation, final approval of manuscript; Y.B.: collection of data, data analysis, final approval of manuscript; S.H.-H.: provision of study material, final approval of manuscript; C.G. and R.Z.: collection and assembly of data, data analysis and interpretation, final approval of manuscript; J.I.G. and H.K.M.: data analysis and interpretation, manuscript writing, final approval of manuscript; K.P.: collection and assembly of data, data analysis and interpretation, provision of study material, manuscript writing, final approval of manuscript; W.R.M.: data analysis and interpretation, manuscript writing, financial support, final approval of manuscript.
Key Words. Induced pluripotent stem cells, Embryonic stem cells, Reprogramming, Extracellular matrix, Collagen IV, Cardiovascular, Hematopoietic
This article has been cited by other articles:
|
|
 |
|
  H. Reinecke, E. Minami, W.-Z. Zhu, and M. A. Laflamme Cardiogenic Differentiation and Transdifferentiation of Progenitor Cells Circ. Res., November 7, 2008; 103(10): 1058 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Condic and M. Rao Regulatory Issues for Personalized Pluripotent Cells Stem Cells, November 1, 2008; 26(11): 2753 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Tulloch, L. Pabon, and C. E. Murry Get With the (Re)Program: Cardiovascular Potential of Skin-Derived Induced Pluripotent Stem Cells Circulation, July 29, 2008; 118(5): 472 - 475. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
